Are you effected by the use of biomarkers in drug development becoming more common in early clinical development? Although the potential benefits of utilising biomarkers have been documented extensively, many of the practicalities of using them have not yet been sufficiently explored.

With an exceptional line-up of speakers, SMi’s Biomarkers in Clinical Trials conference will demonstrate the way forward in designing phase I, II and III trials and give the opportunity to learn more.

This unique event is designed to help you realise the potential of your products in the most efficient way possible and is an essential addition to the calendar of all those working in the industry.

Attend and gain insights into the use of biomarkers as a way of accelerating the approval or withdrawal of a product. You will have the chance to network with industry associates and the opportunity to explore ways in which you can integrate biomarkers into your own drug development processes